ABK Biomedical Secures $35 Million in Series D Financing
ABK Biomedical Achieves Milestone with Series D Funding
ABK Biomedical, Inc., a trailblazer in the medical device sector, has made significant strides by successfully completing an oversubscribed Series D financing round, raising a remarkable US$35 million. This important milestone comes as the company amplifies its efforts in developing advanced medical devices designed for the treatment of embolic conditions.
Investor Support and Future Endeavors
The Series D financing was primarily led by J.P. Morgan Life Sciences Private Capital, a new investor eager to support ABK Biomedical’s innovative approaches. Established backers including F-Prime, Santé Ventures, and Eight Roads Ventures also joined in this funding round, showcasing strong confidence in the company’s direction and potential.
Impact of Series D Financing
The funds acquired through this financing will be allocated towards enhancing clinical operations, gearing up for the commercialization of the groundbreaking Eye90 microspheres, and fostering further development of the company’s product line. Additionally, resources will be directed to expanding manufacturing capabilities and supply chain operations, ensuring ABK Biomedical can fulfill anticipated market demands effectively.
Expert Opinions on Progress
According to Joe Siletto, a Managing Partner at J.P. Morgan Life Sciences Private Capital, ABK Biomedical's progress since its previous funding round in 2019 has been extraordinary. The FDA has designated Eye90 microspheres as a Breakthrough Device, recognizing the device’s potential to significantly improve treatment for serious conditions. The company is currently executing its Route90 FDA IDE pivotal trial with notable success.
CEO's Perspective on Funding
Mike Mangano, President and CEO of ABK Biomedical, expressed gratitude for the overwhelming interest from investors in this funding round. He highlighted the commitment of ABK Biomedical’s team in reaching their product development goals while performing an intensive FDA IDE pivotal trial. Mangano is optimistic about the Route90 study illustrating the exceptional potential of Eye90 microspheres, especially for patients grappling with liver cancer.
Partnerships and Future Growth
Ketan Patel, M.D., Managing Partner at F-Prime, reflected on the enriching partnership that has succeeded since their initial investment in 2019. He emphasized the innovative design of Eye90 microspheres and its promising delivery mechanism, which positions it well within the burgeoning market segment of Y90 radioembolization. Patel expressed excitement about furthering their investment in ABK's remarkable journey and their shared goals to take a significant market share tailored to Interventional Oncology.
About ABK Biomedical, Inc.
ABK Biomedical, Inc. stands at the forefront of medical device innovation, focusing on therapies that enhance patient outcomes, especially for those dealing with hypervascular tumors. With extensive intellectual property rights, the organization additionally thrives on advanced research and development, striving to produce unique embolotherapy solutions.
It is important to note that Eye90 microspheres are yet to receive approval for use beyond designated clinical trials and remains an investigational product. Nevertheless, ABK Biomedical's unwavering commitment to improving treatment options persists as a hallmark of its operations.
Frequently Asked Questions
What is the purpose of the Series D financing for ABK Biomedical?
The Series D financing aims to support clinical operations and prepare for the commercialization of Eye90 microspheres while fostering product innovation.
Who led the Series D funding round?
The Series D funding round was primarily led by J.P. Morgan Life Sciences Private Capital.
What is the significance of Eye90 microspheres?
Eye90 microspheres have received Breakthrough Device Designation from the FDA due to their potential to treat critical conditions more effectively.
When was ABK Biomedical's previous funding round?
The previous funding round occurred in 2019, preceding this successful Series D financing.
What is ABK Biomedical focused on?
The company is focused on researching, developing, and commercializing medical device therapies to enhance treatment outcomes for patients.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.